CyCann will acquire during the Cypriot medicinal cannabis tender process in 2025 the necessary license needed to cultivate, export and import for scientific and medicinal purposes CyCann will use that license to distribute premium produce consisting of EU-GMP compliant cannabis flower, concentrates and extracts.
THC Flower
- Medical applications
- Pharmaceutical products
THC Oil
- Medical applications
- Pharmaceutical products
- Created from flower trim/wastage
Proprietary THC Flower
- Medical applications
- Pharmaceutical products
EU-GMP Quality Standards
- Exceeds GACP and FDA equivalencies
- Exceeds ISO equivalencies
The Cultivation Yields
From our state of the art glass multi-tunnel cultivation facility, a 10,000 m2 (1 Hectares) of twin greenhouse facilities and an indoor cultivation facility of 6,500 m2 on a total plot of land 100,000 m2, which provides enough scope to expand and scale our operations.
CyCann will initially undergo the relevant audits and licensing requirements for THC medical cannabis cultivation in 2025, 18 months after that, cultivation operations will begin in 2026/2027.
The operation has been designed following proven methods, that include 2 integrated greenhouses in a multi tunnel cultivation facility, and an indoor cultivation facility on a flowering cycle ensuring a steady flow of production reducing costs, minimizing risks and increasing production quality.
We are forecasting initial annual production of approximately 3,600 Kg of EU-GMP THC medicinal cannabis flower, and 1320 Kg of full spectrum EU-GMP THC oil, a monthly production yield of 300 Kg of flower and 110 Kg of oil.